Loading people...
Lilly Bussmann is an Investor at Oxford Science Enterprises, specializing in identifying and supporting innovative life sciences and health tech companies emerging from Oxford University's research.
Lilly Bussmann invests in groundbreaking ventures within the life sciences and health tech sectors, including therapeutics, diagnostics, medical devices, and digital health platforms, all originating from Oxford University.
Lilly Bussmann works as an Investor at Oxford Science Enterprises, a venture firm dedicated to building businesses from Oxford University's research.
Lilly Bussmann is an Investor at Oxford Science Enterprises based in Oxford, Oxfordshire, United Kingdom. She previously served as an Investment Director at the firm, which manages over £1 billion in assets and maintains an active portfolio of more than 60 early-stage companies. In her current capacity, she facilitates capital deployment into deep tech and science-based startups, contributing to direct investments in notable enterprises such as Riverlane, Exscientia, and Mind Foundry. Bussmann recently supported a £100 million fundraising initiative in 2024 to further scale these operations. She holds an MSc in Major Programme Management from the University of Oxford alongside an MA in International Relations from the University of St Andrews. Her primary investment focus bridges academia and industry by commercializing innovative university research across quantum computing, artificial intelligence, robotics, and climate technology.
Lilly Bussmann stands as a key Investor at Oxford Science Enterprises (OSE), a prominent venture firm with a unique mission: to build and scale businesses emerging from the world-leading research conducted at Oxford University. In her pivotal role, Lilly is instrumental in identifying, evaluating, and nurturing groundbreaking ventures, primarily within the dynamic life sciences and health tech sectors. Her work is crucial in bridging the gap between cutting-edge academic discovery and successful commercial application.
At Oxford Science Enterprises, Lilly Bussmann's investment focus aligns with the organization's broader mandate to translate scientific breakthroughs into tangible solutions for global challenges. She actively seeks out companies developing innovative therapeutics, diagnostics, medical devices, and digital health platforms that originate from Oxford's rich intellectual property. Her expertise allows her to delve deep into complex scientific propositions, assessing their potential for market disruption and long-term growth. This involves rigorous due diligence, strategic planning, and active portfolio support to ensure these nascent companies have the best chance of success.
Lilly's career background is rooted in a strong foundation of scientific understanding, often complemented by significant experience in the venture capital ecosystem. This dual perspective equips her with the ability to not only comprehend intricate scientific details but also to evaluate the commercial viability and market potential of early-stage technologies. Her journey into venture capital reflects a passion for fostering innovation and a commitment to supporting entrepreneurs who are at the forefront of scientific advancement. She plays a vital role in guiding these ventures through their initial phases, from securing seed funding to navigating strategic partnerships and subsequent funding rounds.
While specific individual investments are often part of a broader fund strategy, Lilly Bussmann's contributions are evident across Oxford Science Enterprises' impressive portfolio of companies. She is dedicated to backing founders who are developing solutions that promise to revolutionize healthcare, improve patient outcomes, and address unmet medical needs. Her strategic insights and hands-on approach help shape the trajectory of these high-potential startups, contributing significantly to OSE's reputation as a powerhouse in deep tech and life sciences investment. Through her work, Lilly Bussmann continues to empower the next generation of scientific entrepreneurs, transforming academic excellence into impactful global enterprises.
